A prospective observational safety study of patients with <scp> <i>BRAF</i> <sup>V</sup> </scp> <sup>600</sup> ‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)Pippa Corrie, Piotr Rutkowski, Patrick Terheyden et al.|British Journal of Dermatology|2018Cited by 4
National Status Reports (Poster Presentation)M. Blombäck, Martin J. Inwood, Donald E. Colburn et al.|Haemostasis|2009Cited by 0
Questions and Answers (Workshop III)M. Blombäck, Martin J. Inwood, Donald E. Colburn et al.|Haemostasis|2009Cited by 0